Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 534: | Line 534: | ||
"title" : "Bioresorbable scaffolds versus metallic stents in routine PCI", | "title" : "Bioresorbable scaffolds versus metallic stents in routine PCI", | ||
"pmid" : "28402237" | "pmid" : "28402237" | ||
}, | |||
{ | |||
"timestamp" : "2024-10-17T17:34:57Z", | |||
"briefDesignDescription" : "Nitrofurantoin vs. fosfomycin in UTI", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/article-abstract/2679131", | |||
"pageid" : 3640, | |||
"pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/2679131/jama_huttner_2018_oi_180034.pdf", | |||
"trainingLevel" : "Medical Student", | |||
"citation" : "Huttner A, <i>et al</i>. \"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial\". <i>JAMA</i>. 2018. 319(17):1781-1789.", | |||
"subspecialties" : "Infectious Disease;Emergency Medicine", | |||
"expansion" : "", | |||
"statusUsableDate" : "2012-03-01", | |||
"briefResultsDescription" : "Nitrofurantoin improved outcomes uncomplicated UTI", | |||
"published" : "2018-03-01", | |||
"pageName" : "AIDA-WP2", | |||
"diseases" : "Urinary Tract Infection", | |||
"abbreviation" : "AIDA-WP2", | |||
"title" : "Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial", | |||
"pmid" : "29710295" | |||
}, | }, | ||
{ | { | ||
| Line 3,878: | Line 3,897: | ||
"title" : "Fidaxomicin versus Vancomycin for Clostridium difficile Infection", | "title" : "Fidaxomicin versus Vancomycin for Clostridium difficile Infection", | ||
"pmid" : "21288078" | "pmid" : "21288078" | ||
}, | |||
{ | |||
"timestamp" : "2024-10-17T17:57:15Z", | |||
"briefDesignDescription" : "Mineralocorticoid antagonist in CKD/T2DM", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2025845", | |||
"pageid" : 4384, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2025845", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Bakris GL, <i>et al</i>. \"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2020. 383(23):2219-2229.", | |||
"subspecialties" : "Nephrology;Endocrinology", | |||
"expansion" : "Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease", | |||
"statusUsableDate" : "2024-10-17", | |||
"briefResultsDescription" : "Mineralocorticoid antagonist slows CKD progression", | |||
"published" : "2020-10-23", | |||
"pageName" : "FIDELIO-DKD", | |||
"diseases" : "Chronic Kidney Disease;Diabetes Mellitus", | |||
"abbreviation" : "FIDELIO-DKD", | |||
"title" : "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", | |||
"pmid" : "33264825" | |||
}, | }, | ||
{ | { | ||